Participant Protection in Phase 1 Pediatric Cancer Trials

JAMA Pediatr. 2019 Jan 1;173(1):8-9. doi: 10.1001/jamapediatrics.2018.3629.

Authors

Jonathan Kimmelman¹, Marcin Waligora², Holly Fernandez Lynch^{3

4}

Affiliations

¹ Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada.
² Research Ethics in Medicine Study Group (REMEDY), Department of Philosophy and Bioethics, Jagiellonian University Medical College, Krakow, Poland.
³ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.

PMID: 30419141
DOI: 10.1001/jamapediatrics.2018.3629

No abstract available

MeSH terms

Child
Clinical Trials, Phase I as Topic / ethics*
Clinical Trials, Phase I as Topic / standards
Ethics Committees, Research / ethics
Ethics Committees, Research / standards*
Humans
Neoplasms / therapy*
Patient Rights / ethics*
Patient Selection / ethics*
Risk
Third-Party Consent / ethics*
United States